← ANALYST RATINGS · TIPRANKS
Arbutus Biopharma (ABUS): analyst forecast and price target
Analyst consensus
0 Buy0 Hold0 Sell
Ratings of 0 analysts in the last 3 months · top analysts only12-month forecast
Based on 0 price targets given in the last 3 months, the average target is —, the highest —, the lowest —. The average is — from the last price of $4.22.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.00 → $4.50−10.0% | Buy | +6.6% | Reiterated | 17.10.26on TipRanks 14:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Buy | +6.6% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.50 → $5.00−9.1% | Buy | +18.5% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.00 → $4.50−10.0% | Buy | +6.6% | Reiterated | 09.10.26on TipRanks Oct 8 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.50 → $5.00−9.1% | Buy | +18.5% | Reiterated | 07.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $5.00 → $4.50−10.0% | Hold | +6.6% | Reiterated | 07.10.26on TipRanks 19:05 | — | |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $7.00 | Buy | +65.9% | Reiterated | 11.12.25on TipRanks Feb 2 14:55 | +1.5%next day +1.9% · 5 days −0.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Arbutus Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.02 (from $-0.02 to $-0.02). Last quarter: $-0.03.
Sales
Next quarter’s sales estimate — $1M (from $1M to $1M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Arbutus Biopharma
- CEO: Lindsay Androski
- Employees: 19
- 701 Veterans Circle, Warminster, PA, 18974, US
- www.arbutusbio.com
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 454 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗